NCT00005778View on ClinicalTrials.gov

High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2000

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions
Lupus Erythematosus, Systemic
Interventions
DRUG

High-dose immunoablative therapy

"1. High dose cyclophosphamide for 4 days.~2. NIH monthly IV cytoxan for 6 months followed by quarterly for 2 years."

Trial Locations (3)

19102

Drexel University School of Medicine, Division of Hematology/Oncology, Philadelphia

21205

Johns Hopkins University Division of Rheumatology, Baltimore

53226

Medical College of Wisconsin, Division of Rheumatology, Milwaukee

All Listed Sponsors
lead

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

NCT00005778 - High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide | Biotech Hunter | Biotech Hunter